Compare Sprott Uranium Miners ETF (URNM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sprott Uranium Miners ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Sprott Uranium Miners ETF trades at $55.4, while State Street SPDR S&P Biotech ETF trades at $159.4. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals.
| URNM | XBI | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Broad Market / Factor |
52-Week High | $83.99 | $164.28 |
52-Week Low | $44.14 | $86.92 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
URNM trades at $55.39, up 1.45% today, with a bullish technical signal supported by moving averages. Recent news highlights nuclear energy's role in meeting AI power demand, with government funding and international deals creating positive momentum. The ETF focuses on uranium miners, offering concentrated exposure to the nuclear supply chain.
The outlook for URNM is positive due to growing nuclear energy demand from AI data centers and government support, though risks include uranium price volatility and concentrated miner exposure. Wall Street sentiment is mixed, with some analysts favoring pure-miner funds while others caution on valuation gaps versus spot prices.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
